Local News: Ashburn, VA 

 | 

Sign Up

 | 

Sign In

GlaxoSmithKline

GlaxoSmithKline News Editors

News Widget

Display the GlaxoSmithKline news headlines on your website.

Get the Topix Headlines Widget

Share & bookmark

RSS icon mobile icon

GlaxoSmithKline News

News on GlaxoSmithKline (Ticker: GSK) continually updated from thousands of sources around the net.

Thursday May 16 | Daily Mail

Market Report: GlaxoSmithKline tipped for Danish drug deal

Ever since GSK in December 2006 broke a then industry record by licensing a drug for leukaemia from Genmab for 1.6bn, taking a 10 per cent stake in the process, the pharmaceutical world has expected GSK to one day launch a full-scale cash offer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Food and Drug Administration

Wed May 15, 2013

Fortune

Dirty medicine

On the morning of Aug. 18, 2004, Dinesh Thakur hurried to a hastily arranged meeting with his boss at the gleaming offices of Ranbaxy Laboratories in Gurgaon, India, 20 miles south of New Delhi.

Comment?

Related Topix: Biotech, Ranbaxy Laboratories, World News, India, Asia Travel, Delhi, India Travel, India Travel, Travel, GlaxoSmithKline, Medicine, Healthcare Industry

Tue May 14, 2013

Freshnews

OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of...

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells , or tumor-initiating cells, today announced clinical progress with its Anti-Notch2/3 product candidate, which will trigger an $8 million milestone payment from the company's strategic collaborator GlaxoSmithKline .

Comment?

Related Topix: Startups, OncoMed Pharmaceuticals, Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Oncology, Health, Lung Cancer, Pancreatic Cancer

AmericanBankingNews.com

GlaxoSmithKline's "Buy" Rating Reaffirmed at TheStreet

's stock had its "buy" rating reiterated by equities research analysts at TheStreet in a research note issued to investors on Tuesday, AnalystRatingsNetwork reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline

The Motley Fool

Who Benefits From This Market Moving Biotechnology Partnership?

Brian is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

Comment?

Related Topix: Blog News, Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Marketing

Mon May 13, 2013

BioSpace

Genable Technologies Ltd Appoints Annette Clancy as Chairman of the Board

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! DUBLIN, Ireland, 13th May 2013: Genable Technologies Ltd., a bio-pharmaceutical company developing new gene medicines to treat 'dominant' genetic diseases, today announced the appointment of Annette Clancy as Chairman of the Board.

Comment?

Related Topix: Frank Sinatra, Jazz, Ireland, World News, Genetics, Medicine, Pharmacology, Biotech, GlaxoSmithKline, Healthcare Industry

Bangor Daily News

Wall Street ends near flat after recent highs; healthcare climbs

U.S. stocks closed little changed on Monday, pausing after hitting record highs last week, but strength in health care issues helped to keep declines in check.

Comment?

Related Topix: Financial Markets, Biotech, Elan Corporation Plc, Medicine, GlaxoSmithKline, Healthcare Industry

Insider Monkey

3 FTSE 100 Shares Hitting New Highs: GlaxoSmithKline plc (GSK), BT...

The FTSE 100 set a five-and-a-half-year record of 6,638 points last Friday, and though the index is down from that today at 6,617, it still looks like hanging on to the 6,600 level -- even if that absolute value is ultimately meaningless.

Comment?

Related Topix: Biotech, Telecom, BT Group, Medicine, Healthcare Industry

AmericanBankingNews.com

GlaxoSmithKline Given "Buy" Rating at Citigroup

's stock had its "buy" rating reiterated by investment analysts at Citigroup in a note issued to investors on Monday, ARN reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline

BioSpace

GlaxoSmithKline's Breo Ellipta Receives Regulatory Approval in U.S.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! LONDON, UK, 13 May, 2013 - Skyepharma PLC , the expert oral and inhalation drug delivery company, announces that the United States Food and Drug Administration has approved the New Drug Application for BREOa ELLIPTAa , a combination product submitted by ... (more)

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, SkyePharma, Food and Drug Administration

Fox News

London Markets: GSK, Shell Lead U.K. Stocks To 8th Day Of Gains

U.K. stocks managed to eke out an eighth straight day of gains on Monday, as Royal Dutch Shell PLC rose after announcing a share buyback and GlaxoSmithKline PLC climbed after a new drug approval.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Food and Drug Administration, Business News

Local Tech Wire

Elan to pay $1B for a share of Theravance's royalties from GSK

Elan Corp. agreed to pay $1 billion for a share of the royalties on new drugs from Theravance Inc.

Comment?

Related Topix: Startups, Theravance, Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, South San Francisco, CA

Insider Monkey

The City News: Antofagasta plc (ANTO), Rolls-Royce Holding PLC (RR), GlaxoSmithKline plc (GSK) & More

Editor's Note: Related tickers: Wal-Mart Stores, Inc. , Tesco Corporation , Goldman Sachs Group, Inc.

Comment?

Related Topix: Mining, Antofagasta, Biotech, Medicine, Healthcare Industry, IGN Entertainment, Fox Interactive Media, Retail, Wal Mart Stores, Tesco, Energy, Oil & Gas

Sun May 12, 2013

RTE.ie

Elan in $1 billion royalty deal with Theravance

Elan will make a once off payment of $1 billion to the company in exchange for a 21% stake in future royalty payments from four respiratory programmes which Theravance has developed with GlaxosmithKline.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry

The Motley Fool

A Closer Look at GlaxoSmithKline's Dividend Potential

Dividend income accounts for around two-thirds of total returns, the actual rate of return taking into account both capital and income appreciation.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry

Sat May 11, 2013

AmericanBankingNews.com

GlaxoSmithKline's "Hold" Rating Reaffirmed at Deutsche Bank

's stock had its "hold" rating restated by equities researchers at Deutsche Bank in a report issued on Wednesday, Analyst Ratings Network.com reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Investment Banking, Financial Services, Jefferies Group, Investment Services

Fri May 10, 2013

Voice of America

Umbilical Cord Cleanser Cuts Infant Mortality

Save the Children, in its State of the World's Mothers report this week, identified this intervention as a key strategy to saving as many as one million babies worldwide who die each year on their first day of life.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry

BioSpace

FDA Approves GlaxoSmithKline/Theravance, Inc. Drug for COPD Lung Disease

GlaxoSmithKline plc and Theravance, Inc. today announced that the US Food and Drug Administration has approved BREO ELLIPTA as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease , including chronic bronchitis and/or emphysema.

Comment?

Related Topix: Startups, Food and Drug Administration, Theravance, Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Chronic Obstructive Pulmonary Disease, Health, Chronic Bronchitis

Vancouver Sun

FDA approves once-a-day inhaler drug for lung disease from GlaxoSmithKline and Theravance

One of Vancouver's two inimitable "Hobbit Houses" is on the market for an asking price of $2.86 million.

Comment?

Related Topix: Startups, Theravance, Biotech, Food and Drug Administration, Medicine, GlaxoSmithKline, Healthcare Industry, Home Listing, Home

The Advocate

Price is right for Tasmania's poppy growers

Poppy Growers Tasmania has concluded negotiations with GlaxoSmithKline and despite a desire to cut prices due to the high Australian dollar and other influences, the company has agreed to hold prices firm across the board.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry

Ashburn Jobs